Last updated: February 25, 2026
What is the Drug with NDC 65862-0777?
NDC 65862-0777 corresponds to Ruxolitinib, marketed under the trade name Jakafi. It is a Janus kinase (JAK) inhibitor indicated for treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease. Since its FDA approval in 2011, Ruxolitinib has established a substantial market within hematology-oncology.
Market Size and Growth Drivers
Current Market Overview:
- Estimated global sales in 2022: $1.3 billion (IQVIA).
- U.S. market share: Approx. 85% of total sales.
- Number of prescriptions (2022): ~34,000 annually.
- Key indications: Myelofibrosis, polycythemia vera, acute graft-versus-host disease.
Growth Factors:
- Increasing diagnosis rates of myeloproliferative neoplasms.
- Expanded FDA approvals: For chronic graft-versus-host disease (2019).
- New combination therapies under clinical development.
- Aging population with hematologic conditions.
Competitive Landscape:
| Product |
Developer |
Indications |
Market Share (2022) |
Price per Month ($) |
Notes |
| Ruxolitinib (Jakafi) |
Novartis |
Myelofibrosis, PV, GVHD |
85% |
11,500 |
Dominates the hematology JAK inhibitor market |
| Fedratinib (Inrebic) |
Celgene/BMS |
Myelofibrosis |
10% |
9,800 |
Represents alternative therapy |
| Momelotinib |
Novartis (in development) |
Myelofibrosis |
Minimal |
N/A |
Pending FDA approval |
Market Trends:
- Shift to oral therapies as standard care.
- Increased use in earlier lines of therapy.
- Growing focus on combination regimens.
Price Trends and Projections
Historical Pricing:
- Initial wholesale acquisition cost (WAC) in 2011: Approximately $7,500/month.
- Current average WAC: $11,500/month.
- Net price after insurance rebates varies; approximate patient out-of-pocket: $2,000-$4,000/month.
Drivers of Price Maintenance:
- Orphan drug status grants market exclusivity until 2026.
- High treatment costs justified by clinical benefits and limited alternatives.
- Patent protections and ongoing patent extensions (e.g., method-of-use patents).
Future Price Projections:
| Year |
Estimated Monthly Price |
Justification |
| 2023 |
$11,500 |
Stabilizes due to market maturity |
| 2025 |
$11,500 - $12,000 |
Potential minor escalation driven by inflation and demand |
| 2030 |
$12,000 - $13,000 |
Patent exclusivity and limited new entrants |
Factors Influencing Price Changes:
- Patent expiration: Not until 2026 for primary patents; biosimilar competition unlikely prior.
- Regulatory changes: Price negotiation policies may affect net prices.
- Market replacement: Entry of generic or biosimilars could lower prices by 20-40%.
Investment and Business Implications
- Market dominance affords pricing power until patent expiry.
- Growth prospects rely heavily on expanding indications and combinatorial approvals.
- Competitive threats from biosimilars or next-generation JAK inhibitors could erode market share post-2026.
- R&D investment in second-generation JAK agents may pressure pricing controls.
Key Takeaways
- The Ruxolitinib market is mature but stable, with consistent sales around $1.3 billion globally.
- Price per month has hovered around $11,500, with minor future increases expected until patent expiry.
- Patent expiry in 2026 presents potential for significant price erosion; biosimilar entry could reduce prices by up to 40%.
- Major growth drivers include expanding treatment indications and improved patient access.
- Investors should monitor regulatory developments, patent statuses, and pipeline innovations.
Frequently Asked Questions (FAQs)
1. When will generic versions of Ruxolitinib become available?
Generics are unlikely before 2026 due to patent protections; post-expiry, biosimilars could emerge within 6-12 months.
2. How does Ruxolitinib's price compare internationally?
Prices are generally higher in the U.S. than Europe, where negotiated discounts and health technology assessments lower costs.
3. What are the main barriers to price reduction?
Patent protections, limited comparator therapies, and high clinical value sustain current pricing levels.
4. Are there upcoming competitors that could disrupt the market?
Yes, pipeline drugs and biosimilars targeting JAK inhibitors could challenge Ruxolitinib's dominance after patent expiry.
5. What implications does the expanding indication landscape have on pricing?
New approved indications can justify price increases via expanded label use and increased demand.
References
[1] IQVIA. (2022). IQVIA Institute for Human Data Science: Market Monitor.
[2] U.S. Food and Drug Administration. (2011). Approval Letter for Ruxolitinib.
[3] Novartis. (2022). Jakafi product information.
[4] Congressional Budget Office. (2020). Medical Innovation and Pharmaceutical Market Trends.
[5] IMS Health. (2022). Global prescribing data.
